The U.K.'s National Health Service falls short in promoting clinical drug trials, resulting in delays in patient enrollment, according to Dr. Jonathan Sheffield of the NHS National Institute for Health Research's clinical research network. "The loss from the current situation is that new therapies take longer to be developed because there are fewer patients to form a study group," Sheffield said.

Related Summaries